Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment
Dexamethasone is a synthetic glucocorticoid commonly used for the prevention and management of side effects in cancer patients undergoing chemotherapy. While it is effective as an anti-emetic and in preventing hypersensitivity reactions, dexamethasone depletes peripheral blood lymphocytes and impact...
Main Authors: | Wayne J. Aston, Danika E. Hope, Alistair M. Cook, Louis Boon, Ian Dick, Anna K. Nowak, Richard A. Lake, W. Joost Lesterhuis |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-11-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1641390 |
Similar Items
-
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
by: Nicola Principe, et al.
Published: (2022-05-01) -
Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models
by: Candelaria Ines Cámara, et al.
Published: (2023-03-01) -
Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion
by: von Mässenhausen, Anne, et al.
Published: (2023) -
Dexamethasone/phenytoin interactions: neurooncological concerns
by: Swiss Medical Weekly
Published: (2002-07-01) -
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
by: Przemyslaw Wielgat, et al.
Published: (2021-02-01)